"The voice for cancer physicians and their patients in Massachusetts."

FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma

01 Nov 2021 9:32 AM | Katy Monaco (Administrator)

Zanubrutinib has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) previously treated with at least one anti-CD20-based regimen.  More Information.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software